Crystalline complexes of fluticasone-2-furoate

• US 7,592,329 B2
• Filed: 02/04/2003
• Issued: 09/22/2009
• Est. Priority Date: 02/04/2002
• Status: Active Grant

• Current Assignee: GlaxoSmithKline Intellectual Property Management Limited (GSK plc)
• Original Assignee: Glaxo Group Limited (GSK plc)
• Inventors: Crowe, David Malcolm, Craig, Andrew, Jacewicz, Victor Witold, Noga, Brian, Seager, John Frederick, Millan, Michael John, Theophilus, Andrew Lewis, Biggadike, Keith, Coote, Steven John, Nice, Rosalyn Kay
• Primary Examiner(s): Krass; Frederick
• Assistant Examiner(s): Webb; Walter E
• Application Number:
  US10/503,114
• Publication Number:
  US 20050043284A1
• Time in Patent Office: 2,422 Days
• Field of Search: 514/180, 514/179, 514/171, 514/172, 424/46, 424/405
• US Class Current: 514/172
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/44 Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
• CPC Class Codes: C07J 17/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton cardanolide, bufanolide C07J19/00
• CPC Class Codes: C07J 31/00 Normal steroids containing one or more sulfur atoms not belonging to a hetero ring

Abstract

There is provided a crystalline complex comprising a compound of formula (I)

in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P2₁2₁2₁ having unit cell dimensions of about 12.5±1.0 §, 15±1.0 §, and 16.2±1.0 § when determined at either 120K or 150K.

Claims

1. A crystalline complex comprising a compound of formula (I)

2. A complex according to claim 1 wherein the guest molecule is liquid at ambient temperature and pressure.

3. A complex according to claim 1 wherein the guest molecule is ε

-caprolactam.

4. A complex according to claim 1 wherein the guest molecule is selected from the group consisting of t-butylamine and cyclohexylamine.

5. A complex according to claim 1 wherein the guest molecule is cyclohexanone.

6. A complex according to claim 1 wherein the guest molecule is pyridine.

7. A complex according to claim 1 wherein the guest molecule is t-butylamine.

8. A complex according to claim 1 wherein the guest molecule is cyclohexylamine.

9. A complex according to claim 1 wherein the molar ratio of compound of formula (I) to guest molecule is 1:

2.0 to 1;

0.3.

10. A pharmaceutical composition comprising a complex according to claim 1 together with a physiologically acceptable diluent or carrier.